New Non-Invasive Tests Show Potential for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A prospective, multicenter diagnostic accuracy study published in The Lancet evaluated non-invasive biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD). The study, involving 1590 participants across 13 countries, found that while single markers had variable performance, multimarker panels, particularly a proteomic panel, demonstrated strong diagnostic performance for detecting at-risk MASH (metabolic dysfunction-associated steatohepatitis). These findings are significant for early diagnosis, therapy selection, and clinical trial enrollment for MASLD, especially with the advent of regulatory-approved pharmacological treatments.